Stoke Therapeutics (STOK) Short-term Investments (2021 - 2026)

Stoke Therapeutics' Short-term Investments history runs 6 years deep, the most recent figure standing at $187.9 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 127.72% year-over-year to $187.9 million; the TTM figure through Mar 2026 stood at $187.9 million (up 127.72% YoY), while the FY2025 annual figure was $200.4 million, up 125.44% from the prior year.
• Short-term Investments for Q1 2026 stood at $187.9 million, down from $200.4 million in the prior quarter.
• The five-year high for Short-term Investments was $209.1 million in Q1 2022, with the low at $75000.0 in Q2 2024.
• The 5-year median for Short-term Investments is $102.5 million (2022), against an average of $105.0 million.
• The sharpest annual moves came in 2024 and 2025: Short-term Investments tumbled 99.81% in 2024, then surged 219788.0% in 2025.
• Stoke Therapeutics' Short-term Investments stood at $116.0 million in 2022, then tumbled by 91.42% to $10.0 million in 2023, then surged by 793.45% to $88.9 million in 2024, then soared by 125.44% to $200.4 million in 2025, then retreated by 6.27% to $187.9 million in 2026.
• Business Quant data shows STOK's Short-term Investments at $187.9 million in Q1 2026, $200.4 million in Q4 2025, and $164.9 million in Q3 2025.